Dose-Response Effects of a 6-Week Progressive Resistance Training Program on Premenstrual Syndrome in Adolescent Girls
調査の概要
詳細な説明
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Dr.Rida Zafar, MSWHPT
- 電話番号:03368753273
- メール:rida.zafar@riphah.edu.pk
研究連絡先のバックアップ
- 名前:Dr Summra Andleeb, MS-OMPT
- 電話番号:0345-0617872
- メール:sammra.andleeb@riphah.edu.pk
研究場所
-
-
Federal
-
Islamabad、Federal、パキスタン、051
- 募集
- Kens college model town humak and community model town
-
コンタクト:
- Dr.Rida Zafar
- 電話番号:03368753273
- メール:rida.zafar@riphah.edu.pk
-
Islamabad、Federal、パキスタン、051
- 募集
- Kid city high school
-
コンタクト:
- Dr.Rida Zafar
- 電話番号:03368753273
- メール:rida.zafar@riphah.edu.pk
-
主任研究者:
- Amina Rizwan, MSPT(WH)
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Diagnosed with Premenstrual Syndrome (PMS) based on PSST screening tool.
- Not currently engaged in any structured resistance or exercise training program.
- Medically cleared to participate in moderate-intensity resistance training.
- Provided written informed consent for participation.
Exclusion Criteria:
- Current use of hormonal therapy or oral contraceptives.
- History of endocrine disorders (e.g., PCOS, thyroid dysfunction).
- Any musculoskeletal or cardiovascular condition limiting exercise participation.
- Ongoing psychiatric medication or diagnosed depression/anxiety disorder.
- Participation in a structured exercise or resistance training program within the last 3 months.
- Use of analgesics, anti-inflammatory, or hormonal medications during the study period.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Progressive Resistance Training Group
Participants allocated to this arm will receive a supervised 6-week progressive resistance training program performed three times per week on non-consecutive days.
Each session will last 45-60 minutes.
|
A supervised progressive resistance training program delivered three sessions per week for six weeks. Exercise intensity is gradually increased using the Borg Rating of Perceived Exertion (RPE) scale. A warm up session will be done before resistance training exercise and Cool down for 5-10 minutes will be done exercise. Participants will follow the FITT prescription for their resistance exercises. Week 1-2 (DOSE 1) Intensity: Low. Bodyweight or dumbbells (RPE 7-11/20). Sets & Reps: 2 sets of 25-30 reps. Volume: High. Focus on mastering technique. Week 3-4 (DOSE 2) Intensity: moderate. Bodyweight or dumbbells (RPE 12-14/20). Sets & Reps: 2 sets of 20-25 repetitions. Volume: Moderate. Focus on mastering technique. Week 5-6(DOSE 3) Intensity: high. Dumbbells (RPE 15-16/20). Sets & Reps: 2 sets of 15-20 repetitions. Volume: Low. |
|
アクティブコンパレータ:Low-Intensity Resistance Training Group
Participants allocated to this arm will receive a supervised low-intensity resistance training program for six weeks.
Sessions will be conducted three times per week, lasting 45-60 minutes each.
Participants will perform the same standardized resistance exercises as the experimental group; however, exercise intensity will remain low throughout the intervention without progressive overload.
|
Participants of this group will receive the same standardized exercises as the experimental group. Exercise intensity remains constant at low intensity throughout the intervention period without progressive increase. Before exercise the participants will perform warm up and after exercise they will perform cool down, same as the experimental group. The FITT protocol for this group is as following: Week 1-2 (DOSE1) Intensity: low Body weight. or Dumbbells (RPE 7-11/20). Sets & Reps: 2 sets of 15repetitions. Volume: Low. Focus on mastering technique. Week 3-4 (DOSE 2) Intensity: low. Bodyweight or dumbbells (RPE 7-11/20). Sets & Reps: 2 sets of 20 repetitions. Volume: Moderate. Focus on mastering technique Week 5-6(DOSE 3) Intensity: Low. Bodyweight or dumbbells (RPE 7-11/20). Sets & Reps: 2 sets of 25 reps. Volume: High. Focus on mastering technique. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Premenstrual Symptoms Screening Tool (PSST)
時間枠:Assessments will be conducted at baseline, week 2, week 4, week 6, and at 3-month follow-up
|
The primary outcome of this study is the severity of premenstrual syndrome symptoms, measured using the Premenstrual Symptoms Screening Tool (PSST).
The PSST is a self-reported questionnaire used to assess physical, psychological, and behavioral symptoms related to PMS, including mood swings, irritability, anxiety, fatigue, bloating, breast tenderness, and difficulty concentrating.
It also evaluates how these symptoms affect daily activities, school performance, and social relationships.
Each item is scored on a 4-point Likert scale ranging from "none" to "severe."
Higher scores indicate greater PMS severity..
|
Assessments will be conducted at baseline, week 2, week 4, week 6, and at 3-month follow-up
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Quality of Life (QoL)
時間枠:Quality of life will be assessed at baseline, immediately after the 6-week intervention, and at 3-month follow-up using the WHOQOL-BREF questionnaire.
|
Quality of life will be assessed using the World Health Organization Quality of Life Questionnaire (WHOQOL-BREF).
This questionnaire contains 26 items and evaluates four domains: physical health, psychological health, social relationships, and environmental well-being.
Each item is rated on a 5-point Likert scale, with higher scores representing better quality of life.
The WHOQOL-BREF is a reliable and valid tool commonly used in clinical and research settings to assess overall well-being.
|
Quality of life will be assessed at baseline, immediately after the 6-week intervention, and at 3-month follow-up using the WHOQOL-BREF questionnaire.
|
協力者と研究者
捜査官
- 主任研究者:Rida Zafar, WHPT、Riphah International University
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- Amina Rizwan
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。